1.	Dworetzky, M., Cohen, S., Cohen, S. G. & Zelaya-Quesada, M. Portier, Richet, and the discovery of anaphylaxis: A centennial. J. Allergy Clin. Immunol. 110, 331–336 (2002).
2.	Simons, F. E. R., Ardusso, L. R. F. & Bilò, M. B. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. World Allergy Organ. J. 2,13–37 (2011).
3.	Simons, F. E. R. 9. Anaphylaxis. J. Allergy Clin. Immunol. 121, 402–407 (2008).
4.	Bloom, B., Simpson, J. L. Tables of Summary Health Statistics for U.S. Children: 2015 National Health Interview Survey. Natl. Cent. Heal. Stat. 7, 6 (2016).
5.	Turner P.J., Gowland M.H., Sharma V., Ierodiakonou D., Harper N., Garcez T., Pumphrey R., Boyle R.J .Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992-2012. J. Allergy Clin. Immunol. 135, 956-963.e1 (2015).
6.	Tejedor Alonso, M. A., Moro Moro, M., Múgica García, M. V. Epidemiology of anaphylaxis. Clin. Exp. Allergy 45, 1027–1039 (2015).
7.	Hochstadter E., Clarke A., De Schryver S., LaVieille S., Alizadehfar R., Joseph L., Eisman H., Ben-Shoshan M. Increasing visits for anaphylaxis and the benefits of early epinephrine administration: A 4-year study at a pediatric emergency department in Montreal, Canada. J. Allergy Clin. Immunol. 137, 1888-1890e4 (2016).
8.	Kindt, T. J., Goldsby, R. A., Osborne, B. A., Kuby, J. Kuby Immunology. Chapter 16 (W. H. Freeman, 2007).
9.	Reber, L. L., Hernandez, J. D., Galli, S. J. The pathophysiology of anaphylaxis. J. Allergy Clin. Immunol. 140, 335–348 (2017).
10.	Chapman, J., Lalkhen, A. G. Anaphylaxis. in Anaesthesia & Intensive Care Medicine 18, 16–21 (2017).
11.	Stone, S. F., Brown, S. G. A. Mediators Released During Human Anaphylaxis. Curr. Allergy Asthma Rep. 12, 33–41 (2012).
12.	PerkinElmer. ChemDraw.
13.	Kemp, S. F., Lockey, R. F. Anaphylaxis: A review of causes and mechanisms. J. Allergy Clin. Immunol. 110, 341–348 (2002).
14.	Simons F.E., Frew A.J., Ansotegui I.J., Bochner B.S., Golden D.B., Finkelman F.D., Leung D.Y., Lotvall J., Marone G., Metcalfe D.D., Müller U., Rosenwasser L.J., Sampson H.A., Schwartz L.B., van Hage M., Walls A.F. Risk assessment in anaphylaxis: Current and future approaches. J. Allergy Clin. Immunol. 120, 2–24 (2007).
15.	Phadia.com. ImmunoCAP Tryptase. (2012). Available at: http://www.phadia.com/da/Products/Allergy-testing-products/ImmunoCAP-Lab-Tests/ImmunoCAP-Tryptase/. (Accessed: 30th August 2017)
16.	Cayman. Histamine EIA kit. Available at:  https://www.caymanchem.com/product/589651. (Accessed: 20th August 2017)
17.	Jahn, U., Galano, J.-M., Durand, T. Beyond prostaglandins--chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angew. Chem. Int. Ed. Engl. 47, 5894–5955 (2008).
18.	Balgoma D., Larsson J., Rokach J., Lawson J.A., Daham K., Dahlén B., Dahlén S.E., Wheelock C.E. Quantification of lipid mediator metabolites in human urine from asthma patients by electrospray ionization mass spectrometry: Controlling matrix effects. Anal. Chem. 85, 7866–7874 (2013).
19.	Jerschow, E., Lin, R. Y., Scaperotti, M. M. & McGinn, A. P. Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations. J. Allergy Clin. Immunol. 134, 1318-1328.e7 (2014).
20.	Miyazaki, E., Kumamoto, T. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin. Exp. Allergy 39, 72–80 (2008). 
21.	Higashi N., Mita H., Ono E., Fukutomi Y., Yamaguchi H., Kajiwara K., Tanimoto H., Sekiya K., Akiyama K., Taniguchi M. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J. Allergy Clin. Immunol. 125, 1084-1091.e6 (2010).
22.	Cross, T. G. & Hornshaw, M. P. Can LC and LC-MS ever replace immunoassays? J. Appl. Bioanal. 2, 108–116 (2016).
23.	Fernández-Peralbo, M. A., Luque de Castro, M. D. Preparation of urine samples prior to targeted or untargeted metabolomics mass-spectrometry analysis. TrAC - Trends Anal. Chem. 41, 75–85 (2012).
24.	Arsenault, J. C. Beginner’s Guide to SPE : Solid-Phase Extraction. (Waters Corporation, 2012).
25.	Karst, U. Wilfried M.A. Niessen: Liquid chromatography–mass spectrometry (Third edition). Anal. Bioanal. Chem. 389, (2007).
26.	McMaster, M. C. LC MS - A Practical User’s Guide. (John Wiley & Sons, Ltd., 2005).
27.	Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. & Whitehouse, C. M. Electrospray ionization for mass spectrometry of large biomolecules. Science. 246, 64–71 (1989).
28.	Niessen, W. M. A. Liquid Chromatography-Mass Spectrometry, Third Edition. (CRC Press, 2006).
29.	Agilent. Agilent 6200 Series TOF and 6500 Series Q-TOF LC / MS System Concepts Guide The Big Picture. (2014).
30.	Sterz, K., Scherer, G. & Ecker, J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. J. Lipid Res. 53, 1026–1036 (2012).
31.	Armstrong M., Liu A.H., Harbeck R., Reisdorph R., Rabinovitch N., Reisdorph N. Leukotriene-E4 in human urine : Comparison of on-line purification and liquid chromatography – tandem mass spectrometry to affinity purification followed by enzyme immunoassay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 3169–3174 (2009).
32.	Hušek P., Švagera Z., Hanzlíková D., Řimnáčová L., Zahradníčková H., Opekarová I., Šimek P. Profiling of urinary amino-carboxylic metabolites by in-situ heptafluorobutyl chloroformate mediated sample preparation and gas chromatography–mass spectrometry. J. Chromatogr. A 1443, 211–232 (2016).
33.	Bouatra S., Aziat F., Mandal R., Guo A.C., Wilson M.R., Knox C., Bjorndahl T.C., Krishnamurthy R., Saleem F., Liu P., Dame Z.T., Poelzer J., Huynh J., Yallou F.S., Psychogios N., Dong E., Bogumil R., Roehring C., Wishart D.S. The human urine metabolome. PLoS One 8, e73076–e73076 (2013).
34.	Gronwald W., Klein M.S., Zeltner R., Schulze B.D., Reinhold S.W., Deutschmann M., Immervoll A.K., Böger C.A., Banas B., Eckardt K.U., Oefner P.J. Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine. Kidney Int. 79, 1244–1253 (2011).
35.	Kumlin M, Stensvad F, Larsson L, Dahlén B, Dahlén SE. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin. Exp. Allergy 25, 467–479 (1995).
36.	Toewe, A., Balas, L., Durand, T., Geisslinger, G. & Ferreirós, N. Simultaneous determination of PUFA-derived pro-resolving metabolites and pathway markers using chiral chromatography and tandem mass spectrometry. Anal. Chim. Acta 1031, 185–194 (2018).
37.	Lueke A.J., Meeusen J.W., Donato L.J., Gray A.V., Butterfield J.H., Saenger A.K. Analytical and clinical validation of an LC–MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis. Clin. Biochem. 49, 979–982 (2016).
38.	Sasaki A., Fukuda H., Shiida N., Tanaka N., Furugen A., Ogura J., Shuto S., Mano N., Yamaguchi H. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS. Anal. Bioanal. Chem. 407, 1625–1639 (2015).
39.	US FDA Bioanalytical Method Validation Guidance for Industry Bioanalytical Method Validation Guidance for Industry. (2018).
40.	Pugia, M. J., Lott, J. A., Wallace, J. F., Cast, T. K. & Bierbaum, L. D. Assay of creatinine using the peroxidase activity of copper-creatinine complexes. Clin. Biochem. 33, 63–70 (2000).
41.	Monnin, C., Ramrup, P., Daigle-Young, C. & Vuckovic, D. Improving negative liquid chromatography/electrospray ionization mass spectrometry lipidomic analysis of human plasma using acetic acid as a mobile-phase additive. Rapid Commun. Mass Spectrom. 32, 201–211 (2018).
42.	11b-PGF2a (HMDB0010199). Available at: http://www.hmdb.ca/metabolites/HMDB0010199. (Accessed: 12th May 2019)
43.	Leukotriene E4 (HMDB0002200). Available at: http://www.hmdb.ca/metabolites/HMDB0002200. (Accessed: 12th May 2019)
44.	LTE4, Cayman Chemicals. Available at: https://www.caymanchem.com/pdfs/20410.pdf. (Accessed: 12th May 2019)
45.	Thakare, R., Chhonker, Y. S., Gautam, N., Alamoudi, J. A. & Alnouti, Y. Quantitative analysis of endogenous compounds. J. Pharm. Biomed. Anal. 128, 426–437 (2016).
46.	Clinical Laboratory Improvement Amendments (CLIA). Available at: https://wwwn.cdc.gov/CLIA/Resources/IQCP/. (Accessed: 12th May 2019)
47.	11β-Prostaglandin F2α ELISA Kit, Cayman Chemicals. Available at: https://www.caymanchem.com/product/516521. (Accessed: 12th May 2019)
48.	Willemsen M.A., Rotteveel J.J., de Jong J.G., Wanders R.J., IJlst L., Hoffmann G.F., Mayatepek E. Defective metabolism of Leukotriene B4 in the Sjögren–Larsson Syndrome. J. Neurol. Sci. 183, 61–67 (2001).
49.	Cayman. Leukotriene E4 EIA Kit. Available at: https://www.caymanchem.com/pdfs/501060.pdf. (Accessed: 3rd December 2017)